Anti-nausea medication associated with increased survival in triple-negative breast cancer
A study found that the anti-nausea drug aprepitant is associated with improved survival and reduced recurrence in women with early-stage breast cancer, especially in those with the aggressive triple-negative subtype, suggesting potential for broader use during chemotherapy.